Vial Denial and the GLP-1 Shortage

The Pound of Cure Weight Loss Podcast

Episode 21 of The Pound of Cure Weight Loss podcast is titled, Vial Denial and the GLP-1 Shortage. The name comes from our Economics of Obesity segment where we discuss the GLP-1 shortage and how it’s caused by the inability to procure injector pens. Canada recognized this issue a while back and allowed pharmaceutical companies to use single dose vials instead of injector pens. So why aren’t we using single dose vials in the United States? I have some opinions about it.
Our In the News segment comes from an article in Reuters about how Viking Therapeutics is developing a weight loss medication that can be taken orally. The Medication is similar to Mounjaro and Zepbound in that it is both a GLP-1 and a GIP and the initial studies show better weight loss with more responders than Ozempic, Wegovy, Mounjaro, and Zepbound in the injectable version. Is the oral version going to be as effective? Tune in to find out!
In our Patient Story, we talk to Shenelle who is a very successful recovering alcoholic and drug addict. She started her weight loss journey after getting sober and is now a coach for bariatric patients struggling with food addiction. Her story of perseverance is truly inspiring.
Zoe introduces the Emotional Eating Umbrella in our Nutrition segment. This is a concept she created to help quantify and qualify all the different attributes that encompass emotional eating so that we can develop new coping strategies for each individual trigger.
Finally, we cover a few of our listener submitted questions including, thoughts on the Keto+ ACV gummies, Omeprazole after surgery, and nutrition and medication changes before pregnancy.